Rhinomed Limited is pleased to report that it has finalised an exclusive supply agreement with SureScreen Australia to supply Rhinoswabs and Rhinoswab Juniors for inclusion in SureScreen’s class-leading range of lateral flow point of care test kits in the Australian, New Zealand, Singapore and South Pacific markets.
The first product to market will be the ARTG registered SureScreen SARS-CoV-2 Antigen Rapid test Cassette Gold for children, which features Rhinomed’s novel Rhinoswab Junior. This will be the first SARS-CoV-2 rapid antigen test kit designed specifically for children aged 4-12 on the Australian market.
Globally, children remain a critically vulnerable population group for SARS-Cov-2, yet the traumatic nature of swabbing with traditional nasal swabs leads to inconsistent testing. A study conducted by the Royal Children’s Hospital Melbourne had previously shown that 74% of parents are concerned the COVID-19 test might be stressful or painful for their child with 30% indicating these worries are very likely to stop them from taking their child for a test. A further 2021 trial by the Murdoch Children’s Research Institute and Royal Children’s Hospital Melbourne showed that the Rhinoswab Junior has not only clinical equivalence to the highly invasive combined nose and throat swabs but was preferred by eight out 10 children. SureScreen Australia has successfully registered this new rapid antigen test kit with the Rhinoswab Junior on the ARTG enabling immediate sales.